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A B S T R A C T
Systemic inflammation and oxidative stress are the most important features of chronic obstructive pulmonary disease
(COPD). The presence of oxidative stress in the airways of smokers, the largest population of COPD patients, is a conse-
quence of direct inhalation of cigarette smoke and increased inflammation-related production of reactive oxygen species.
On the other hand, oxidative stress appears to be the key component of many processes associated with chronic inflamma-
tion. We intend to examine whether serum C-reactive protein (CRP) concentration and gamma-glutamyltransferase
(GGT) activity might be used as auxiliary markers in monitoring level of oxidative stress and inflammation in clinically
stable COPD. We also investigated influence of cigarette smoking on these two systemic parameters. Catalytic activity of
GGT and concentration of CRP were determined in sera of COPD patients (N=109) and in healthy controls (N=51) by
using standard spectrophotometric method and immunoturbidimetric method, respectively. Concentration of CRP and
activity of GGT were increased in COPD patients, as compared to healthy controls (p<0.05). We found a significant posi-
tive correlation between those two parameters in COPD patients (r=0.202, p=0.0371). Our results showed no difference
in GGT activity (p=0.606) or CRP concentration (p=0.573) between groups of patients when subdivided according to the
severity of the disease. Smoking did not have a significant impact on CRP and GGT values in COPD patients and
healthy controls. We showed an increase of serum CRP and GGT values in COPD patients, and we suggest that serum
GGT activity might also represent an inflammation/oxidative stress marker. It seems that COPD patients present higher
serum CRP and GGT values than healthy subjects independently from their smoking habits.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the
fifth most common cause of death in general population
and the only chronic disease that has continuously sho-
wed an increase in mortality. It is a systemic inflam-
matory disease that begins with the impairment in the
lung function and morphology, and progresses with an
increase in airflow limitations, further destruction of
lung parenchyma and development of extra-pulmonary
complications1. The most important elements in the patho-
genesis of COPD are inflammation and development of
oxidative stress2,3. In COPD, inflammation is occurring
in the airways, pulmonary parenchyma, blood vessels
and has generalised effects. The presence of oxidative
stress in the airways of smokers, the largest population
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of COPD patients, is a consequence of direct inhalation
of cigarette smoke and increased inflammation-related
production of reactive oxygen species. Cigarette smoke is
a complex mixture of more than 4700 chemical com-
pounds, including high concentrations of free radicals
and other oxidants4. Oxidative stress appears to be the
key component of many processes associated with chro-
nic inflammation. It produces direct damaging effects to
the lungs, and activates the molecular mechanisms that
aggravate lung inflammation.
Association of impaired lung function and an increa-
sed concentration of CRP was first suggested by Kony et
al5. Recently, serum CRP was used as a marker for the
airways obstruction and inflammation in severe state of
asthma and in COPD, irrespective of the smoking history
or concomitant ischemic heart disease. However, admin-
istration of the inhaled corticosteroids produced a signifi-
cant decrease in CRP levels6,7. Based on these findings
CRP was proposed as a supplementary marker for the in-
flammation of upper respiratory airways.
Glutathione (gamma-glutamylcysteinilglycine; GSH)
is the most important cellular antioxidant. The mem-
brane-bound enzyme gamma-glutamyltransferase (GGT)
initiates metabolism and turnover of GSH, and plays an
important role in GSH homeostasis8. Activity of GGT as
a possible marker of oxidative stress that is present in
the pathology of lung and other diseases has recently
come into focus9,10. However, depending on local condi-
tions in the tissue, GGT might express both anti-oxida-
tive and pro-oxidative function10,11. Reference range for
the serum activity of GGT are rather broad and higher
GGT activities, although still within the reference range,
might be used as an early and sensitive marker of oxida-
tive stress12–17. In addition, GGT regulates the catabo-
lism of leukotriene C4 (LTC4) and its conversion into
leukotriene D4 (LTD4), thus showing a pro-inflamma-
tory effects. A positive correlation that was established
between GGT activity, concentration of CRP and some
other markers of inflammation has also put GGT on the
list of putative markers for inflammation18,19. The pre-
cise role of GGT in different physiological and pathophy-
siological conditions is currently under serious investiga-
tion.
The aim of this study was to examine serum CRP con-
centration and GGT activity in COPD patients and heal-
thy individuals. We hypothesized that these two systemic
parameters might be used as auxiliary markers in moni-
toring level of oxidative stress and inflammation in clini-
cally stable COPD. We also investigated influence of ciga-
rette smoking on CRP and GGT values.
Materials and Methods
Study design
The study included 109 patients with clinically stable
COPD (33 smokers, 28 ex-smokers, 48 non-smokers) and
the control group of 51 healthy subjects (18 smokers, 15
ex-smokers, 18 non-smokers). Smokers were defined as
current smokers who smoke more that 2 cigarettes/day
and those who quit smoking up to 6 months before enrol-
ment in the study; ex-smokers were defined as persons
who smoked during their lifetime, quit smoking more
than 6 months before enrolment in the study and have
pack years value >1; non-smokers were defined as never
smokers.
Inclusion criterion for the patients was a clinical diag-
nosis of COPD according to GOLD (Global Initiative for
Chronic Obstructive Lung Disease)1 – clinical examina-
tion and FEV1/FVC <0.70, as measured on first admis-
sion at the Department for Pulmology in the General
Hospital »Dr. Ivo Pedi{i}«, Petrinja, Croatia. Exclusion
criteria for both COPD patients and healthy subjects
were presence of pulmonary diseases (except COPD for
the patients), infective and inflammatory diseases, neo-
plastic pathologies, renal, gastrointestinal, endocrine
and hepatic diseases, and excessive alcohol consumption
(³40 g/day).
All the patients were in the stable phase of the disease
for at least 3 months without the need for hospitalization
and therapy modification. Their medication therapy con-
sisted of a combination of bronchodilators, anticholiner-
gic agents, theophylline, and inhaled corticosteroids.
Spirometry was performed for all participants. Blood
samples were collected between 7:00 a.m. and 9:00 a.m.
Sera were separated by centrifugation at 3500 rpm for 10
min, and CRP concentration and GGT activity were de-
termined immediately. Patients were classified according
to the severity of disease, as suggested by GOLD1. Stage
II – moderate COPD (N=30): FEV1/FVC <0.70, 50% £
FEV1 <80% predicted value; stage III – severe COPD
(n=50): FEV1/FVC <0.70, 30% £ FEV1 <50% predicted
value; stage IV – very severe COPD (N=29): FEV1/FVC
<0.70, FEV1 <30% predicted value or FEV1 <50% pre-
dicted value and with chronic respiratory failure. The
study was approved by the medical ethics committee of
the Hospital, and informed consent was obtained from
all study subjects.
Methods
Catalytic activity of GGT was determined by using
standard spectrophotometric method, according to IFCC
suggestion (Herbos Diagnostics, d.o.o., Sisak, Croatia),
on automatic analyser Alcion (Abbott Diagnostics, Abbot
Park, IL, USA)20. Reference range for the serum activity
of GGT: male 11–55 U/L, female 9–35 U/L. Determina-
tion of CRP concentration was performed by using im-
munoturbidimetric method on automatic analyser Di-
mension Xpand Plus (Siemens Healthcare Diagnostics,
USA)21. Reference range for concentration of CRP: male,
female ³20 years: <5 mg/L.
Statistical analysis
Statistical analysis was performed with Med Calc
9.4.2.0. (MedCalc Software, Mariakerke, Belgium). All
data were tested for normal distribution by Kolmogorov-
-Smirnov test and differences between the means by
student t-test. Data for non-normally distributed varia-
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bles were expressed as medians with interquartile range,
and tested by Mann-Whitney test. Statistical analysis for
multiple comparisons was analysed by one way analysis
of variance (ANOVA) and Kruskal-Wallis test. Correla-
tion coefficients were calculated using Pearson and
Spearman correlation coefficient. Statistical significance
was defined as p<0.05. Each biochemical marker was
tested using Receiver Operating Characteristic Curve
(ROC), for pairs of diagnostic specificity and diagnostic
sensitivity.
Results
Characteristics of COPD patients and healthy con-
trols are presented in Table 1. Healthy subjects were of
good general health, had normal lung function, as shown
by FEV1 (% predicted) and FEV1/FVC values, and were
younger than patients with stable COPD. We tested the
influence of age on activity of GGT and concentration of
CRP in sera and we found no correlation between age
and CRP or GGT values niether in patients’ group (CRP
– rs=–0.0249, p=0.7958; GGT – rs=–0.0558, p=0.5656)
nor in healthy subjects (CRP – r=0.08571, p=0.5498;
GGT – r=–0.04104, p=0.7749).
Significant differences in FEV1 (% predicted), FEV1/
FVC and BMI were observed between the groups. In ad-
dition, COPD patients had a significantly higher number
of pack years values than controls (Table 1).
We measured catalytic activity of GGT and concentra-
tion of CRP in sera and found a statistically significant in-
crease in GGT activity (for 63%) and in CRP concentration
(for 79%) in all COPD patients when compared to healthy
controls (p<0.05). Figure 1 represents catalytic activity of
GGT and concentration of CRP in sera of COPD patients
assigned to three stages according to the disease grades
(GOLD II, III, and IV). Since data did not show normal dis-
tribution, results are presented as median and interquar-
tile range. In all COPD stages we found a significant in-
crease in GGT activity when compared to healthy controls
(p<0.05). Similarly, significantly higher CRP concentra-
tions were found in all COPD stages when compared to
healthy controls (p< 0.05). However, there were no signifi-
cant differences either in GGT activity (p=0.606) or CRP
concentration between COPD stages (p=0.573).
Each biochemical marker was further tested using
ROC curve for diagnostic specificity and sensitivity (Fig-
ure 2). Analysis showed that cut-off value for serum CRP
concentration of 11.86 mg/L exhibited a good diagnostic
accuracy (AUC=0.808, p=0.0001), with 94.12% specificity
and 59.63% sensitivity. Serum GGT activity measurement
(cut off value of 22 U/L) displayed a fair diagnostic accu-
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TABLE 1






Age* 71 (65–76) 52 (46–56)
Male, N (%) 82 (75) 21 (41)
Female, N (%) 27 (25) 30 (59)
BMI adjusted for age (kg/m2) 21.0±5.4** 26.4±4.5
FEV1 (% predicted) 41±14** 106±15
FEV1/ FVC (%) 62.0±10.6** 86.2±6.6
Pack years* 50 (32–75)** 20 (15–30)
COPD – chronic obstructive pulmonary disease, BMI – body
mass index, calculated as the ratio weight (kg) divided by height
(m2), FEV1 (% predicted) – forced expiratory volume in 1 second,
corrected for gender, age, body mass and height, FEV1/FVC –
FEV1 as percentage of forced vital capacity, FVC, pack years (for
smokers and ex-smokers) – duration of smoking multiplied by
the number of cigarettes smoked per day, and divided by 20.
Data shown are X ± SD, except for * where median and
interquartile range are presented.
** p<0.001 in comparison with controls
Fig. 1. Catalytic activity of GGT (A) and concentration of CRP
(B) in sera of healthy controls and COPD patients subdivided by
disease severity (GOLD grades). GGT – gamma-glutamyltrans-
ferase, CRP – C-reactive protein, COPD – chronic obstructive
pulmonary disease, GOLD – global initiative for chronic obstruc-
tive lung disease, *significant difference in stages II, III and IV
when tested against healthy controls, p<0.05.
racy (AUC=0.702, p=0.0001), with 60.78% specificity and
73.39% sensitivity. The cut-off value for GGT activity for
all COPD patients, regardless of stage, was equal.
In order to test diagnostic specificity and sensitivity
in particular GOLD grade, we performed ROC analysis
with COPD patients divided into subgroups. ROC analy-
sis of CRP data showed a good diagnostic accuracy for
stage IV (cut off value 11.31 mg/L, AUC=0.865, specific-
ity 92.16%, sensitivity 75.86%, p=0.0001). For stages II
and III, CRP determination exhibited a fair diagnostic
accuracy (stage II – AUC=0.791, specificity 94.12%, sen-
sitivity 56.67%, p=0.0001; stage III – AUC=0.786, speci-
ficity 80.39%, sensitivity 68.00%, p=0.0001). ROC analy-
sis for GGT measurement demonstrated a poor diagnos-
tic accuracy for stage II (AUC=0.657, specificity 60.78%,
sensitivity 63.33%, p=0.0150), and a fair diagnostic accu-
racy for stages III and IV (stage III – AUC=0.723, speci-
ficity 60.78%, sensitivity 78.00%, p=0.0001; stage IV –
AUC=0.714, specificity 66.67%, sensitivity 72.41%, p=
0.0006).
Spearman coefficient of correlation showed a signifi-
cant positive correlation between serum CRP and GGT
activity (r=0.202, p=0.0371) in COPD patients group.
As shown in Figure 3, smoking did not affect CRP con-
centration and GGT activity either in COPD patients or in
healthy controls. Only GGT values between healthy smok-
ers and healthy ex-smokers differed significantly (p<0.05).
When COPD patients were subdivided both by disease se-
verity and smoking habits, similar results were obtained
(Table 2). Within a particular smoking category (smokers,
ex-smokers, non-smokers), CRP and GGT were increased
in patients as compared to healthy subjects, but no signifi-
cant differences were present among COPD stages.
Discussion
We evaluated the possibility of applying serum CRP
concentration and GGT activity as markers in monitor-
ing level of inflammation and oxidative stress in COPD
patients. Population-based studies have observed posi-
tive dose-response relations between serum GGT (mostly
within normal range) and markers of oxidative stress,
and inverse association with serum and dietary antioxi-
dant vitamins15,22,23. Thus, it was suggested that serum
GGT, even within its normal range, is a sensitive and
early marker of oxidative stress18. In addition, GGT may
be involved in the inflammation cascade13. It has been
hypothesized that elevation in GGT might occur before
an elevation in CRP, if oxidative stress leads to a subse-
quent inflammatory response18. It is well established
that imbalance between oxidants and antioxidants is im-
plicated in the pathogenesis of COPD, with oxidative
stress being involved in amplification of chronic inflam-
matory processes1.
In this study, we found an increase of CRP and GGT
values in sera of the individuals with clinically stable
COPD, as compared with healthy subjects. This is in
agreement with previously published data for CRP7,24–28,
but in contrast with results for GGT obtained from the
study using a limited number of COPD patients (29
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Fig. 3. Catalytic activity of GGT (A) and concentration of CRP
(B) in sera of healthy controls and COPD patients subdivided by
smoking history: control smokers (C – S), control ex-smokers (C –
EXS), control non-smokers (C – NS), COPD smokers (S), COPD
ex-smokers (EXS), COPD non-smokers (NS). GGT – gamma-glu-
tamyltransferase, CRP – C-reactive protein, COPD – chronic ob-
structive pulmonary disease, *significant difference between
healthy smokers and healthy ex-smokers, p<0.05.
Fig. 2. ROC curve for serum CRP concentration and GGT activ-
ity in COPD patients. CRP – C-reactive protein, GGT – gamma-
-glutamyltransferase, COPD – chronic obstructive pulmonary
disease.
COPD patients)17. As GGT activity has been commonly
used as a marker for alcohol consumption or liver dys-
function, we excluded from this study all the individuals
(healthy subjects and COPD patients) who excessively
drunk alcohol beverages as well as those with confirmed
liver diseases. In addition, we measured activity of ala-
nine aminotransferase and aspartate aminotransferase
in sera of the persons enrolled in the study, and found
that enzyme activities were within the reference range
both for healthy controls and COPD patients, indicating
a normal liver function (data not shown).
Some authors have shown that serum GGT was posi-
tively associated with CRP and certain other systemic
markers of inflammation, in a dose-dependent man-
ner18,19,23,28. However, those studies involved only healthy
subjects. Best to our knowledge, this study is the first re-
port exploring the relation between serum GGT and CRP
in COPD patients, and we found a significant positive
correlation between those two parameters.
Our results showed no significant difference either in
GGT activity or CRP concentration when the patients
were subdivided according to the disease grades (GOLD
II, III, and IV). However, CRP rose with increasing sever-
ity of COPD in some other studies24,26,29. Although stable
COPD is undoubtedly characterised by systemic inflam-
mation process, it is still unclear whether it reflects the
continuous intensification of the lung inflammation as-
sociated with the disease progression, or inflammation in
the peripheral blood aggravates only during the exacer-
bation episodes. Thus, the amount of each inflammatory
marker might not necessarily differ significantly among
disease stages during the stable phase of the disease, and
it would be interesting to monitor the values of those sys-
temic parameters and their association during exacerba-
tion.
Cigarette smoking is by far the most commonly en-
countered risk factor for COPD. In our study, smoking
did not have a significant impact on CRP and GGT val-
ues in COPD patients and healthy controls. The only ex-
ception was difference in GGT activity between healthy
smokers and healthy ex-smokers, but it is quite possible
that a small number of participants within a particular
group (18 and 15, respectively) affected the results obtai-
ned. Thus, it seems that COPD patients present higher
serum CRP and GGT values than controls independently
from smoking habits. The same conclusion was reached
for GGT activity and CRP concentration in other stu-
dies7,17, although Gan and co-workers demonstrated in-
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TABLE 2
CRP CONCENTRATION AND GGT ACTIVITY IN SERA OF COPD PATIENTS SUBDIVIDED INTO GOLD STAGES AND HEALTHY
CONTROLS, WITH RESPECT TO THEIR SMOKING HISTORY
COPD patients (N=109) Healthy subjects
(N=51)Stage II (N=30) Stage III (N=50) Stage IV (N=29)
CRP (mg/L)
Smokers
(N=8) (N=13) (N=12) (N=18)
a
16.09 (9.24–114.50) 10.11 (6.48–50.26) 22.27 (10.98–36.63) 8.41 (6.16–11.02)
Ex-smokers
(N=8) (N=13) (N=7) (N=15)
b
13.90 (8.04–27.04) 10.57 (7.60–32.03) 27.60 (12.99–82.13) 6.38 (3.00–8.49)
Non-smokers
(N=14) (N=24) (N=10) (N=18)
c
12.59 (7.69–20.86) 26.54 (10.34–71.39) 18.16 (7.93–38.45) 7.98 (4.57–9.30)
GGT (U/L)
Smokers
(N=8) (N=13) (N=12) (N=18)
d
37.5 (33.5–199.5) 28.0 (22.3–65.8) 30.0 (24.5–47.5) 16.0 (13.0–21.0)
Ex-smokers
(N=8) (N=13) (N=7) (N=15)
16.5 (15.0–35.5) 37.0 (27.0–82.8) 28.0 (18.0–39.3) 28.0 (22.0–42.5)
Non-smokers
(N=14) (N=24) (N=10) (N=18)
e
26.0 (18.0–40.0) 32.5 (21.0–59.5) 43.5 (23.0–52.0) 18.0 (13.0–25.0)
COPD – chronic obstructive pulmonary disease, CRP – C-reactive protein, GGT – gamma-glutamyltransferase. Data are expressed as
median (interquartile range: 25th-75th percentile).
a Significant difference between Stage IV and healthy smokers, P<0.05
b Significant difference between the multiple groups (COPD ex-smokers: Stage II, Stage III, Stage IV) compared with healthy ex-smok-
ers, p<0.05
c Significant difference between the multiple groups (COPD non-smokers: Stage II, Stage III, Stage IV) compared with healthy non-
-smokers, p<0.05
d Significant difference between the multiple groups (COPD smokers: Stage II, Stage III, Stage IV) compared with healthy smokers,
p<0.05
e Significant difference between the multiple groups (COPD non-smokers: Stage III, Stage IV) compared with healthy non-smokers,
p<0.05
fluence of smoking on CRP30. As the understanding of
the importance of risk factors for COPD has grown, so
has the recognition that essentially all risk for COPD re-
sults from a particular gene-environment interaction.
Little is known about the reason why some persons with
the same smoking history develop clinically important
COPD whereas others do not, and it was suggested that
it is due to diversity in genetic predisposition to the
disease1. In a previous study which demonstrated in-
creased CRP concentrations in COPD patients independ-
ent of smoking, the authors speculated that each person
has an inherited inflammatory genetic profile, so called
»phenotype of CRP responders«, and thus the differences
may precede the exposure to the environmental factors7.
However, although the most common, cigarette smoke is
not the only trigger for COPD occurrence. Numerous
other inhaled noxious agents may also contribute to re-
spiratory symptoms and COPD by increasing the lungs
total burden of inhaled particles and gases1. Subjects en-
rolled in our study experienced a long-term and intensive
exposure to air pollution from the nearby oil refinery and
thermal power plant, and the number of COPD and
asthma patients is rapidly growing in this area. The role
of air pollution in causing COPD is unclear, although it is
associated with adverse effects on lung function31. How-
ever, the concept of total personal exposure to the irri-
tants, such as smoking and pollution, may be more rele-
vant for developing COPD, in addition to the COPD
susceptibility genes.
In this study, we included COPD patients with moder-
ate, severe and very severe stage of the disease, except
those with mild stage (GOLD I) who have not yet experi-
enced a typical and strong symptoms of the disease and
hence are often underestimated. In addition, both our
healthy subjects and COPD patients have different smo-
king habits, and they were classified as smokers, ex-
-smokers and non-smokers. Many studies that analyse
COPD patients combine ex-smokers either with current
smokers or with never smokers, while in the others,
when this subgroup is present separately, ex-smokers are
defined differently. Hence, there is a need for a consensus
in defining who meet criteria for the category of ex-smok-
ers. This could contribute to more accurate exploring of
the influence of smoking on both pulmonary and ex-
tra-pulmonary changes associated with COPD.
Our study has several shortcomings. First, relatively
small sample size (109 COPD patients, 51 healthy con-
trols) is restrictive for an unambiguous conclusions, and
a larger epidemiological study will be needed to assess
the association between increased CRP and GGT values.
Second, we did not assess CRP and GGT in COPD pa-
tients suffering from exacerbation episode. Third, smok-
ing habits of our subjects were self-reported, and mea-
surement of the carboxyhemoglobin should be performed
to confirm smoking status. Despite these potential limi-
tations, we showed an increase of serum CRP and GGT
values in COPD patients, thus supporting the hypothesis
that serum GGT activity might represent an inflamma-
tion/oxidative stress marker in COPD, as already sug-
gested in the case of cardiovascular diseases and meta-
bolic syndrome10. However, more research is needed to
better understand the pathophysiological role of both
CRP and GGT in development and progression of COPD.
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GAMA-GLUTAMILTRANSFERAZA I C-REAKTIVNI PROTEIN U STABILNOJ KRONI^NOJ
OPSTRUKCIJSKOJ PLU]NOJ BOLESTI
S A @ E T A K
Sistemska upala i oksidativni stres su najva`nije zna~ajke kroni~ne opstrukcijske plu}ne bolesti (KOPB). Prisutnost
oksidativnog stresa u di{nim putovima pu{a~a, najve}e populacije pacijenata oboljelih od KOPB-a, je posljedica direk-
tnog udisanja cigaretnog dima i upalom uvjetovanog poja~anog stvaranja reaktivnih kisikovih ~estica. S druge strane,
~ini se da je oksidativni stres klju~na komponenta mnogih procesa povezanih sa kroni~nom upalom. @eljeli smo ispitati
da li se vrijednosti koncentracije C-reaktivnog proteina (CRP) i aktivnosti gama-glutamiltransferaze (GGT) u serumu
mogu koristiti kao pomo}ni markeri u pra}enju razina oksidativnog stresa i upale u klini~ki stabilnoj KOPB. Tako|er
smo ispitali utjecaj pu{enja na ta dva sistemska parametra. Kataliti~ka aktivnost GGT-a i koncentracija CRP-a su odre-
|ene u serumu pacijenata oboljelih od KOPB-a (N=109) i zdravih kontrolnih ispitanika (N=51) koriste}i standardnu
spektrofotometrijsku odnosno imunoturbidimetrijsku metodu. Koncentracija CRP-a i aktivnost GGT-a su bile povi{ene
u pacijenata prilikom usporedbe sa zdravim kontrolama (p<0,05). Prona{li smo statisti~ki zna~ajnu pozitivnu kore-
laciju izme|u ta dva parametra u KOPB pacijenata (r=0,02, p=0,0371). Nismo prona{li razliku u aktivnosti GGT-a
(p=0,606) i koncentraciji CRP-a (p=0,573) izme|u grupa pacijenata podijeljenih prema stupnju te`ine bolesti. Pu{enje
nije imalo zna~ajan utjecaj na vrijednosti CRP-a i GGT-a u KOPB pacijenata niti u zdravih kontrolnih ispitanika. Poka-
zali smo porast vrijednosti CRP-a i GGT-a u serumu pacijenata i pretpostavljamo da aktivnost GGT u serumu mo`e
tako|er predstavljati marker upale/oksidativnog stresa. ^ini se da se u serumu pacijenata oboljelih od KOPB-a nalaze
vi{e vrijednosti CRP-a i GGT-a nego u zdravih ispitanika, neovisno o njihovim pu{a~kim navikama.
